RAPID (RAPID ART Program Initiative for new Diagnoses)



<u>Evidence-Informed for the Structural Intervention Chapter</u>
Evidence-Informed for the Linking and Retention in HIV Care Chapter

POPULATION

> Persons with a new HIV diagnosis

KEY INTERVENTION EFFECTS

- Improved linkage to HIV care
- ➤ Increased ART initiation
- > Improved viral suppression

BRIEF DESCRIPTION

RAPID is a San Francisco citywide initiative to link persons with a new HIV diagnosis to care within 5 days of HIV diagnosis and initiate antiretroviral therapy (ART) within 1 day of the first care visit. Strategies during the first care visit include:

- Counseling and education
- · Medical evaluation
- Baseline laboratory testing
- · Benefits navigation
- Providing ART
- Providing follow up services including appointment with HIV primary care
- Partner services from the San Francisco Department of Public Health Linkage, Integration, Navigation, and Comprehensive Services (LINCS) Program
- Linkage to psychosocial support (housing assistance, substance use treatment, mental health care)

DURATION: One clinic visit, plus limited follow-up visits as needed until patient established in HIV primary care

SETTING: Clinic sites (San Francisco, CA) including several RAPID ART hubs

STUDY YEARS: 2013 – 2017

STUDY DESIGN: Serial cross-sectional

DELIVERERS: Trained HIV providers, LINCS navigators, social workers **DELIVERY METHODS:** Counseling, Navigation services, Partner services

STUDY SAMPLE

The baseline study sample of N = 1,354 providers was characterized by the following:

- 42% White persons
 - 13% Black or African American persons
 - 27% Hispanic, Latino, or Latina persons
 - 13% Asian or Pacific Islander persons
 - 5% Persons identifying as another race or ethnicity
- 89% male persons, 8% female persons, 3% transgender female persons
- 32% persons 13-29 years old; 31% persons 30-39 years old; 37% persons ≥40 years old

STRUCTURAL COMPONENTS

Access - HIV medical care

Immediate (within 5 working days) access to HIV medical care and ART

Capacity Building – Trained staff

 Trained LINCS navigators, social workers, clinicians, and clinic staff on RAPID ART using in-services, medical grand rounds, written materials, and public health detailing program.

KEY INTERVENTION EFFECTS (see **Primary Study** for all outcomes)

- Throughout San Francisco, median time from diagnosis to first care visit decreased by 44%, from 9 to 5 days (p < 0.001) from 2013 to 2017.
- Median time from first HIV care visit to ART initiation decreased by 96% from 28 days to 1 day (p < 0.0001) from 2013 to 2017 and decreased significantly among all sociodemographic and exposure categories.
- Median time from ART initiation to viral suppression decreased by 37% from 79 to 50 days (p = 0.0007) from 2013 to 2017.
- Median time from diagnosis to first viral suppression decreased by 48% from 145 days to 76 days (p < 0.0001) from 2013 to 2017, but this varied widely by sociodemographic and exposure categories.

CONSIDERATIONS

- In a previous pilot study of RAPID ART at Ward 86, San Francisco General Hospital, that included 39 patients with new diagnosis of HIV in 2013 to 2014,* post-intervention participants reported:
 - $_{\odot}$ a lower median time from referral to clinic intake visit than pre-intervention participants (1 vs. 13 days, respectively, p < 0.001)
 - $_{\odot}$ a lower median time from referral to viral suppression than pre-intervention participants (56 vs. 132 days, respectively, p < 0.001)
 - $_{\odot}$ a lower median time from diagnosis to viral suppression than pre-intervention participants (65 vs. 190 days, respectively, p < 0.001)
 - \circ a shorter median time between clinic referral to viral suppression than pre-intervention participants (1.8 vs. 4.3 months, respectively, p < 0.0001)
- Another study with 225 patients who were referred to RAPID at Ward 86 from 2013 2017 found that 95.8% participants achieved viral suppression (< 200 copies/mL) within one year after intake.†
 - o Viral suppression rates were 92.1% at last recorded viral load.

ADVERSE EVENTS

The author did not report adverse events.

FUNDING

• Centers for Disease Control and Prevention (grant number NU62PS924536-01-00)

PRIMARY STUDY

Bacon, O., Chin, J., Cohen, S., Hessol, N., Sachdev, D., Coffey, S., Scheer, S., Buchbinder, S., Havlir, D., & Hsu, L. (2021). Decreased time from human immunodeficiency virus diagnosis to care, antiretroviral therapy initiation, and virologic suppression during the citywide RAPID initiative in San Francisco. Clinical Infectious Diseases, 7(1), e122-e128. doi: 10.1093/cid/ciaa620

Bacon, O., Coffey, S., Hsu, L., Chin, J., Havlir, D., & Buchbinder, S. (2021). <u>Development of a citywide rapid antiretroviral therapy initiative in San Francisco</u>. *American Journal of Preventative Medicine, 61*(5 Suppl. 1), S47–S54. doi: 10.1016/j.amepre.2021.06.001

PREVIOUS STUDIES

* Pilcher, C. D., Ospina-Norvell, C., Dasgupta, A., Jones, D., Hartogensis, W., Torres, S., Calderon, F., Demicco, E., Geng, E., Gandhi, M., Havlir, D. V., & Hatano, H. (2017). The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting. *JAIDS Journal of Acquired Immunodeficiency Syndromes, 74*, 44-51. doi: 10.1097/QAI.000000000001134

†Coffey, S., Bacchetti, P., Sachdev, D., Bacon, O., Jones, D., Ospina-Norwell, C., Torres, S., Lynch, E., Camp, C., Mercer-Slomoff, R., Lee, S., Christopoulos, K., Pilcher, C., Hsu, L., Jin, C., Scheer, S., Havlir, D., & Gandhi, M. (2019). Rapid antiretroviral therapy: High virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population. *AIDS*, *33*(5), 825-832. doi: 10.1097/OAD.0000000000012124

PLEASE CONTACT STUDY AUTHOR FOR TRAINING AND INTERVENTION MATERIALS.

Contact information

Oliver Bacon, MD, MPH San Francisco City Clinic 356 7th Street San Francisco, CA 94103

Email: oliver.bacon@sfdph.org